DK1073754T3 - Fremgangsmåde til fremstilling af proteinmutanter med lille allergen reaktion hos mennesker - Google Patents

Fremgangsmåde til fremstilling af proteinmutanter med lille allergen reaktion hos mennesker

Info

Publication number
DK1073754T3
DK1073754T3 DK99918575T DK99918575T DK1073754T3 DK 1073754 T3 DK1073754 T3 DK 1073754T3 DK 99918575 T DK99918575 T DK 99918575T DK 99918575 T DK99918575 T DK 99918575T DK 1073754 T3 DK1073754 T3 DK 1073754T3
Authority
DK
Denmark
Prior art keywords
humans
preparation
small
allergenic protein
protein mutants
Prior art date
Application number
DK99918575T
Other languages
Danish (da)
English (en)
Inventor
David A Estell
Fiona A Harding
Original Assignee
Genencor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22032273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1073754(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genencor Int filed Critical Genencor Int
Application granted granted Critical
Publication of DK1073754T3 publication Critical patent/DK1073754T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
DK99918575T 1998-04-15 1999-04-14 Fremgangsmåde til fremstilling af proteinmutanter med lille allergen reaktion hos mennesker DK1073754T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/060,872 US6835550B1 (en) 1998-04-15 1998-04-15 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
EP99918575A EP1073754B9 (en) 1998-04-15 1999-04-14 Process for the preparation of protein mutants having lower allergenic response in humans.
PCT/US1999/008253 WO1999053038A2 (en) 1998-04-15 1999-04-14 Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins

Publications (1)

Publication Number Publication Date
DK1073754T3 true DK1073754T3 (da) 2005-05-09

Family

ID=22032273

Family Applications (3)

Application Number Title Priority Date Filing Date
DK08009499.8T DK1997897T3 (da) 1998-04-15 1999-04-14 Mutantproteiner med lavere allergenisk respons hos mennesker og fremgangsmåder til konstruktion, identifikation og fremstilling af sådanne proteiner
DK99918575T DK1073754T3 (da) 1998-04-15 1999-04-14 Fremgangsmåde til fremstilling af proteinmutanter med lille allergen reaktion hos mennesker
DK04016880.9T DK1586649T3 (da) 1998-04-15 1999-04-14 Mutantproteiner med lav allergen reaktion hos mennesker og fremgangsmåder til konstruktion, identificering og fremstilling af sådanne proteiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08009499.8T DK1997897T3 (da) 1998-04-15 1999-04-14 Mutantproteiner med lavere allergenisk respons hos mennesker og fremgangsmåder til konstruktion, identifikation og fremstilling af sådanne proteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04016880.9T DK1586649T3 (da) 1998-04-15 1999-04-14 Mutantproteiner med lav allergen reaktion hos mennesker og fremgangsmåder til konstruktion, identificering og fremstilling af sådanne proteiner

Country Status (20)

Country Link
US (4) US6835550B1 (cs)
EP (3) EP1586649B1 (cs)
JP (1) JP4447774B2 (cs)
KR (1) KR20010034776A (cs)
CN (1) CN1302113C (cs)
AT (2) ATE277189T1 (cs)
AU (1) AU752934B2 (cs)
BR (1) BR9909640A (cs)
CA (1) CA2327311C (cs)
CZ (1) CZ20003789A3 (cs)
DE (3) DE69920434D1 (cs)
DK (3) DK1997897T3 (cs)
ES (2) ES2338319T3 (cs)
ID (1) ID26645A (cs)
IL (2) IL138445A0 (cs)
MX (2) MXPA05003289A (cs)
NO (1) NO20005153L (cs)
NZ (2) NZ506926A (cs)
PL (1) PL343509A1 (cs)
WO (1) WO1999053038A2 (cs)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6967080B1 (en) * 1990-12-05 2005-11-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US20050209121A1 (en) * 1990-12-05 2005-09-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
MA23346A1 (fr) * 1993-10-14 1995-04-01 Genencor Int Variantes de la subtilisine
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
CA2376045A1 (en) * 1999-07-22 2001-02-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
US6946128B1 (en) * 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CA2379712A1 (en) * 1999-07-22 2001-02-01 The Procter & Gamble Company Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
DE60028248T2 (de) * 1999-12-02 2007-03-15 Thromb-X N.V. Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
WO2001041786A1 (en) 1999-12-10 2001-06-14 The General Hospital Corporation METHODS TO STIMULATE INSULIN PRODUCTION BY PANCREATIC β-CELLS
US6855548B2 (en) 2000-02-08 2005-02-15 F. Hoffman-La Roche Ag Use of acid-stable proteases in animal feed
PL203212B1 (pl) * 2000-02-08 2009-09-30 Dsm Ip Assets Bv Zastosowanie trwałej w kwasie proteazy w karmie zwierzęcej oraz w wytwarzaniu kompozycji do stosowania w karmie zwierzęcej, dodatek do karmy zwierzęcej, kompozycja karmy zwierzęcej i sposób obróbki białek roślinnych
US6960462B2 (en) 2000-02-08 2005-11-01 Dsm Ip Assets B.V Use of acid-stable subtilisin proteases in animal feed
EP2258835A1 (en) * 2000-04-28 2010-12-08 Novozymes A/S Lipolytic enzyme variant
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
HUP0402071A2 (hu) * 2001-02-06 2005-01-28 Merck Patent Gmbh. Csökkentett immunogenitású, módosított leptin
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
EP1373296B1 (en) * 2001-03-23 2011-10-05 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7157416B2 (en) * 2001-07-20 2007-01-02 Genencor International, Inc. Stabilization of enzymes
CA2466592A1 (en) * 2001-11-12 2003-05-22 Koen Hellendoorn Modified anti-tnf alpha antibody
US20040209312A1 (en) * 2001-11-13 2004-10-21 Harding Fiona A Identifying and reducing the allergenicity of food proteins
JP2005514026A (ja) * 2001-12-31 2005-05-19 ジェネンコー・インターナショナル・インク 免疫反応の変化を生じるプロテアーゼ、ならびにその製造および利用方法
NZ534198A (en) * 2002-02-26 2005-11-25 Genencor Int Population based assessments and means to rank the relative immunogenicity of proteins
US20050239043A1 (en) * 2002-02-26 2005-10-27 Harding Fiona A Subtilisin carlsberg proteins with reduced immunogenicity
DK1495128T3 (da) * 2002-03-29 2014-08-11 Genencor Int Forstærket proteinekspression i Bacillus
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子
US20050220800A1 (en) * 2002-05-01 2005-10-06 Scott Power D Cytokines and cytokine receptors with reduced immunogenicity
JP2006506964A (ja) * 2002-06-12 2006-03-02 リサーチ　ディベロップメント　ファンデーション 治療剤としての免疫毒素及びその利用
WO2004003186A2 (en) * 2002-06-26 2004-01-08 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
US20040007251A1 (en) * 2002-07-10 2004-01-15 Kimberly-Clark Worldwide, Inc. Cleaners for the control and removal of allergens
BRPI0313080B1 (pt) 2002-07-30 2018-03-13 Danisco Us Inc. Produto de limpeza, seus método de produção e uso
US20040121953A1 (en) * 2002-08-09 2004-06-24 Chirino Arthur J. Thrombopoiesis-stimulating proteins having reduced immunogenicity
ES2291883T3 (es) 2003-02-07 2008-03-01 Novozymes A/S Proteasas.
EP1597363B1 (en) 2003-02-26 2015-07-15 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
EP2500423B1 (en) 2003-02-26 2015-06-17 Danisco US Inc. Amylases producing an altered immunogenic response and methods of making and using the same
JP5009614B2 (ja) * 2003-07-03 2012-08-22 アバター バイオテクノロジーズ，インク． 免疫原性を低減した分子の取得方法
EP2308966A1 (en) 2003-10-10 2011-04-13 Novozymes A/S Protease variants
WO2005042581A2 (en) * 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
WO2005095592A2 (en) * 2004-04-02 2005-10-13 Novozymes A/S Subtilase variants having altered immunogenicity
WO2006033668A2 (en) * 2004-04-09 2006-03-30 Genencor International, Inc. Pcka modifications and enhanced protein expression in bacillus
JP4699450B2 (ja) 2004-04-15 2011-06-08 ジェネンコー・インターナショナル・インク Ｃａｂ分子、ｃｅａを対象とするａｄｅｐｔ構築
US20080220450A1 (en) * 2004-04-26 2008-09-11 Danisco Us, Inc., Genencor Division Population Based Prediction Methods for Immune Response Determinations and Methods for Verifying Immunological Response Data
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US20060275270A1 (en) * 2004-04-28 2006-12-07 Warren William L In vitro mucosal tissue equivalent
US7709256B2 (en) 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US20070141552A1 (en) * 2004-04-28 2007-06-21 Warren William L Automatable artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
JP5795699B2 (ja) 2004-04-28 2015-10-14 サノフィ パスツール ヴァックスデザイン コーポレーション 人工免疫システム：作製および使用方法
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US20090060933A1 (en) * 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
EP2258839B1 (en) 2004-06-21 2015-06-03 Novozymes A/S Proteases
ES2417133T3 (es) * 2005-02-03 2013-08-06 Antitope Limited Anticuerpos y proteínas humanas
JP5153613B2 (ja) * 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
AU2006236905B2 (en) * 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1904531B1 (en) * 2005-07-08 2010-10-06 Pfizer Limited Madcam antibodies
EP1919951B1 (en) * 2005-08-04 2015-01-28 Janssen Biotech, Inc. Anti-tnf-alpha antibodies and methods of use
JP2009511000A (ja) * 2005-09-14 2009-03-19 メディミューン リミテッド シュードモナス外毒素ａｃｄ４＋ｔ細胞エピトープ
EP1963491B1 (en) * 2005-12-21 2011-01-12 VaxDesign Corporation In vitro method of evaluating the potential reaction of an animal to an agent
JP5622358B2 (ja) 2005-12-21 2014-11-12 サノフィ パスツール ヴァックスデザインコーポレーション ｉｎｖｉｔｒｏ胚中心
EP2351830B1 (en) 2006-03-23 2014-04-23 Ajinomoto Co., Inc. A method for producing an L-amino acid using bacterium of the Enterobacteriaceae family with attenuated expression of a gene coding for small RNA
US7709257B2 (en) * 2006-06-27 2010-05-04 Vax Design Corp. Models for vaccine assessment
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
WO2008048537A1 (en) * 2006-10-16 2008-04-24 Danisco Us, Inc. Genencor Division Non-phosphate dish detergents
KR20090088946A (ko) 2006-12-14 2009-08-20 메다렉스, 인코포레이티드 씨디70에 결합하는 인간 항체 및 이의 용도
CN103667323B (zh) 2007-03-12 2016-02-03 丹尼斯科美国公司 经修饰的蛋白酶
WO2008141281A1 (en) 2007-05-10 2008-11-20 Danisco Us Inc., Genencor Division A modified secretion system to increase expression of polypeptides in bacteria
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009048661A1 (en) * 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
CA2709804A1 (en) 2007-12-21 2009-07-30 Danisco Us Inc. Enhanced protein production in bacillus
JP2011516039A (ja) * 2008-03-12 2011-05-26 ヴァックスデザイン コーポレーション 人工免疫系（ａｉｓ）への疾患モデルの組込み
JP5659143B2 (ja) * 2008-03-28 2015-01-28 ダニスコ・ユーエス・インク 細菌性細胞中の遺伝子座を増幅する方法
BRPI0823193A2 (pt) 2008-10-15 2019-09-24 Danisco Us Inc inibidores de protease de bowman birk variantes modificados
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
CN102209778B (zh) * 2008-11-11 2014-10-15 丹尼斯科美国公司 包含丝氨酸蛋白酶变体的组合物和方法
US8753861B2 (en) 2008-11-11 2014-06-17 Danisco Us Inc. Protease comprising one or more combinable mutations
FR2940451B1 (fr) 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
CN102648277B (zh) * 2009-09-25 2015-05-20 诺维信公司 蛋白酶变体的用途
MX2012006616A (es) 2009-12-09 2012-06-21 Procter & Gamble Productos para el cuidado de las telas y el hogar.
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
EP3089991B1 (en) 2013-12-31 2019-08-28 Danisco US Inc. Enhanced protein expression
US10627411B2 (en) 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
KR102588719B1 (ko) 2014-12-16 2023-10-12 다니스코 유에스 인크. 향상된 단백질 발현
WO2016100128A1 (en) 2014-12-19 2016-06-23 Danisco Us Inc Enhanced protein expression
GB201501565D0 (en) * 2015-01-30 2015-03-18 Dupont Nutrition Biosci Aps Method
EP3585910B1 (en) 2017-02-24 2024-03-20 Danisco US Inc. Compositions and methods for increased protein production in bacillus licheniformis
US11879127B2 (en) 2017-08-23 2024-01-23 Danisco Us Inc. Methods and compositions for efficient genetic modifications of Bacillus licheniformis strains
WO2019055261A1 (en) 2017-09-13 2019-03-21 Danisco Us Inc MODIFIED 5 'NON-TRANSLATED REGION (UTR) SEQUENCES FOR INCREASED PROTEIN PRODUCTION IN BACILLUS
EP3461892A3 (en) 2017-09-27 2019-06-12 The Procter & Gamble Company Detergent compositions comprising lipases
DE102017125560A1 (de) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa Reinigungszusammensetzungen, die dispersine iii enthalten
EP3703661A1 (en) 2017-11-02 2020-09-09 Danisco US Inc. Freezing point depressed solid matrix compositions for melt granulation of enzymes
JP7280269B2 (ja) 2018-01-03 2023-05-23 ダニスコ・ユーエス・インク タンパク質の産生増加のための変異及び遺伝子改変バチルス属（ｂａｃｉｌｌｕｓ）細胞、並びにその方法
CN114945665A (zh) 2020-01-15 2022-08-26 丹尼斯科美国公司 用于增强地衣芽孢杆菌中蛋白产生的组合物和方法
US20240352499A1 (en) 2021-08-20 2024-10-24 Danisco Us Inc. Polynucleotides encoding novel nucleases, compositions thereof and methods thereof for eliminating dna from protein preparations

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2926808A1 (de) 1978-07-04 1980-01-17 Novo Industri As Proteaseprodukt mit verringerter allergener wirkung, herstellungsverfahren und waschmittel
US4261868A (en) 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4404128A (en) 1981-05-29 1983-09-13 The Procter & Gamble Company Enzyme detergent composition
JPS58144105A (ja) 1982-02-12 1983-08-27 Kurabo Ind Ltd スケ−ル除去獣毛繊維の製法
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US5204015A (en) 1984-05-29 1993-04-20 Genencor International, Inc. Subtilisin mutants
US5264366A (en) 1984-05-29 1993-11-23 Genencor, Inc. Protease deficient bacillus
US5182204A (en) 1984-05-29 1993-01-26 Genencor International, Inc. Non-human carbonyl hydrolase mutants, vectors encoding same and hosts transformed with said vectors
US5185258A (en) 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
US5801038A (en) * 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
DE3750916T2 (de) * 1986-04-30 1995-06-01 Genencor Int Mutante einer nicht menschlichen Carbonyl-Hydrolase, für diese kodierende DNS-Sequenzen und Vektoren und durch diese Vektoren transformierte Wirte.
US5314692A (en) 1987-08-24 1994-05-24 Cultor Ltd. Enzyme premix for feed and method
WO1989004552A1 (en) 1987-10-30 1989-05-18 Lsi Logic Corporation Method and means of fabricating a semiconductor device package
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US4874070A (en) 1988-02-10 1989-10-17 Eaton Corporation Control for AMT system start from stop operation
DE3841152A1 (de) 1988-12-07 1990-06-13 Hoechst Ag Verwendung von bakterienlysierendem enzymprodukt als zusatzstoff zur verbesserung der futterverwertung in der tierproduktion
US5766898A (en) * 1990-12-05 1998-06-16 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
PT633929E (pt) * 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
DK132892D0 (da) 1992-10-30 1992-10-30 Novo Nordisk As Proteiner
US5593877A (en) * 1993-03-11 1997-01-14 The Rockefeller University Nucleic acid and recombinant production of vespid venom hyaluronidase
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US5820862A (en) * 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9416841D0 (en) 1994-08-19 1994-10-12 Finnfeeds Int Ltd An enzyme feed additive and animal feed including it
US5648219A (en) * 1995-06-07 1997-07-15 Zymogenetics, Inc. Immortalized dendritic cells
JPH10509324A (ja) 1994-11-24 1998-09-14 ノボ ノルディスク アクティーゼルスカブ 抑制されたアレルゲン性を有するポリペプチドの製造のための方法
FI972443L (fi) 1994-12-07 1997-06-09 Novo Nordisk As Polypeptidi, jonka allergeenisuus on vähentynyt
US5951980A (en) * 1995-01-06 1999-09-14 Leuven Research & Development Vzw Identification, production and use of new staphylokinase derivatives with reduced immunogenicity
ATE429490T1 (de) 1995-05-05 2009-05-15 Novozymes As Protease-varianten und verbindungen
US5837517A (en) * 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
JP2000506119A (ja) 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6300116B1 (en) 1996-11-04 2001-10-09 Novozymes A/S Modified protease having improved autoproteolytic stability
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CA2238660A1 (en) 1998-05-22 1999-11-22 Janet Chantler Gene sequences of rubella virus associated with attenuation
ATE390441T1 (de) * 1998-10-30 2008-04-15 Novozymes As Niedrigallergene proteinvarianten
GB9913425D0 (en) * 1999-06-09 1999-08-11 Universitu Libre De Bruxelles Identification and molecular characterisation of proteins expressed in the tick salivary glands

Also Published As

Publication number Publication date
KR20010034776A (ko) 2001-04-25
AU752934B2 (en) 2002-10-03
DE69920434T4 (de) 2006-07-27
EP1073754B9 (en) 2005-01-19
DE69941827D1 (de) 2010-01-28
ES2229703T3 (es) 2005-04-16
DE69920434D1 (de) 2004-10-28
ES2229703T4 (es) 2006-07-16
US6218165B1 (en) 2001-04-17
NZ506926A (en) 2003-10-31
US6835550B1 (en) 2004-12-28
IL138445A0 (en) 2001-10-31
ID26645A (id) 2001-01-25
ES2338319T3 (es) 2010-05-06
EP1073754B1 (en) 2004-09-22
DE69920434T2 (de) 2005-10-13
EP1997897B1 (en) 2012-11-14
ATE452195T1 (de) 2010-01-15
EP1997897A1 (en) 2008-12-03
US6596525B1 (en) 2003-07-22
JP4447774B2 (ja) 2010-04-07
DK1997897T3 (da) 2013-02-11
CA2327311C (en) 2010-03-16
EP1586649B1 (en) 2009-12-16
ATE277189T1 (de) 2004-10-15
MXPA05003288A (es) 2005-09-08
AU3645499A (en) 1999-11-01
NO20005153L (no) 2000-12-11
CA2327311A1 (en) 1999-10-21
WO1999053038A2 (en) 1999-10-21
CN1302113C (zh) 2007-02-28
DK1586649T3 (da) 2010-04-26
JP2002511251A (ja) 2002-04-16
EP1073754A2 (en) 2001-02-07
CZ20003789A3 (cs) 2001-08-15
BR9909640A (pt) 2000-12-19
CN1297484A (zh) 2001-05-30
WO1999053038A3 (en) 2000-02-10
MXPA05003289A (es) 2005-09-08
NZ524596A (en) 2004-09-24
EP1586649A2 (en) 2005-10-19
PL343509A1 (en) 2001-08-27
NO20005153D0 (no) 2000-10-13
US20050137112A1 (en) 2005-06-23
IL138445A (en) 2013-05-30
EP1586649A3 (en) 2005-11-02

Similar Documents

Publication Publication Date Title
DK1073754T3 (da) Fremgangsmåde til fremstilling af proteinmutanter med lille allergen reaktion hos mennesker
DE69938302D1 (de) Neisseria meningitidis antigene und zusammenstellungen
NO994998L (no) Fusjonsproteiner
DE69941567D1 (de) Antigene aus neisseria meningitidis
DK1135498T3 (da) Antistofvarianter med höjere bindingsaffinitet end forældreantistoffer
DK1071792T3 (da) Human protease og anvendelse af en sådan protease til farmaceutiske anvendelser og til reducering af allergeniciteten af ikke-humane proteiner
IL165080A0 (en) Method and reagents for n-alkylating ureides
WO2002085930A3 (de) Immunmodulierende wirkstoffe aus parasitären würmern und verfahren zu deren isolierung
DK0589348T3 (da) Fremgangsmåde til immunkemisk kvantificering af inaktiverede, immunreaktive antigener
WO2003065998A8 (en) Immunoglobulin purification
AU2002257052A8 (en) Reg-like protein immunoglobulin derived proteins, compositions, methods and uses
Larichev The Great Code of Laws of the Vault of Heaven as It Is Depicted on the Bronze Mirror
DE69941961D1 (de) Monoklonale Antikörper gegen humane Thymidylat-Synthase und Hybridomen zu derer Herstellung